Isolated Muscular Sarcoidosis Causing Fever of Unknown Origin: The Value of Gallium-67 Imaging

Neetin Patel, Arthur Krasnow, James L. Sebastian, B. David Collier, Robert S. Hellman, and Ali T. Isitman

Department of Radiology, Nuclear Medicine Section, and Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin

An unusual case of a patient with a long-standing fever of unknown origin (FUO) is presented whose gallium-67 (⁶⁷Ga) images revealed increased activity only in the calf muscles bilaterally. Other imaging modalities also failed to show chest or other abnormal findings. Subsequent biopsy of the right gastrocnemius muscle revealed noncaseating granulomas consistent with the diagnosis of sarcoidosis. When using ⁶⁷Ga to evaluate a patient with a FUO, imaging of the extremities should always be included. Also, when abnormal Ga-67 uptake is present in the extremities, sarcoidosis should be included in the differential diagnosis.

J Nucl Med 1991; 32:319-321

Darcoidosis is a chronic noncaseating granulomatous disease which involves multiple organ systems with thoracic involvement in 95% of the patients. Extrathoracic involvement is less frequent and varies widely among different organs (1-3). Although asymptomatic muscle involvement is thought to occur in 50%-80% of patients, symptomatic involvement is very infrequent (0.5%) and only rarely occurs without associated pulmonary disease (1,4). Occasionally, sarcoidosis can present as the diagnostically challenging patient with a fever of unknown origin (FUO). Scintigraphy can be helpful in determining sites of involvement and activity of disease.

We present an unusual case of a patient with a longstanding FUO whose gallium-67-citrate (⁶⁷Ga) images showed abnormal activity only in the lower extremities. Subsequent biopsy of a calf muscle revealed noncaseating granulomas consistent with sarcoidosis.

Received Jan. 12, 1990; revision accepted Jul. 19, 1990. For reprints contact: Arthur Krasnow, MD, Nuclear Medicine Section, Box 104, Medical College of Wisconsin, 8700 W. Wisconsin Ave., Milwaukee, WI 53226.

CASE REPORT

A 42-yr-old white male was admitted for work-up of an FUO, which he claimed had been present intermittently over the preceding 20 yr but had not been treated with either antibiotics or steroids. In addition, he complained of generalized malaise, fatigue, night sweats, and myalgia of both lower extremities. The physical examination revealed only tender calf muscles without nodularity or skin abnormalities. The lungs, liver, and spleen were all normal and there was no palpable lymphadenopathy. He was anemic with a hemoglobin of 10 g/dl and a slightly elevated white blood cell count of 13,200 without a left shift. Urine cultures, multiple blood cultures, rheumatology profiles, viral serologies, and a PPD skin test were all negative. Serum angiotensin-converting enzyme level (ACE) was normal while chest X-ray (Fig. 1), lower extremity X-rays, and computed tomography scans of the chest, abdomen, and pelvis were unremarkable. A total-body bone scan did not reveal any osseous pathology. A gallium scan was ordered to help search for an occult site of infection. This was preferred over an indium-111-WBC scan because of the chronicity of the patients' complaints.

Seventy-two hours following the i.v. administration of 5 mCi of ⁶⁷Ga images over the entire body were obtained. The only abnormality found was that of multiple small confluent focal areas of increased tracer activity scattered about both calf areas (Fig. 2). The lungs, mediastinum, abdomen, and lymph nodes in other areas showed a normal distribution of ⁶⁷Ga activity (Fig. 3). Muscle biopsy of the right gastrocnemius muscle also revealed noncaseating granulomas consistent with sarcoidosis.

The patient was placed on oral steroid therapy with resolution of both his fever and calf myalgias. A repeat gallium scan could not be obtained because the patient was subsequently lost to follow-up.

DISCUSSION

Sarcoidosis is a granulomatous disorder that primarily affects the lungs and the mediastinal lymph nodes. However, multiorgan disease is also a common manifestation with liver (70%), spleen (50%), skin (10%),




FIGURE 1
Normal PA chest X-ray without hilar or paratracheal lymph node enlargement or interstitial lung disease.

and salivary glands (5%) being frequently involved (1). Although muscle granulomas are also thought to be common, generally the majority do not produce symptoms and nearly all have concomitant pulmonary disease (8). Our patient presented with a FUO, normal chest findings, and tenderness of his leg muscles. The 67 Ga scan convinced the clinicians that a calf muscle biopsy might be helpful. This subsequently led to the diagnosis of sarcoidosis.

There are three different forms of skeletal muscle involvement by sarcoidosis. The main type is painful or painless nodules consisting of noncaseating granulomas of various sizes. A second less common form is that of diffuse infiltration of muscle causing the clinical picture of an acute or subacute polymyositis. The third type presents as a chronic myopathy characterized by symmetrical weakness and atrophy of proximal muscle groups (1). Edan et al. described a patient with muscular sarcoidosis with associated mediastinal adenopathy which most likely represents the polymyositis form of the disorder (8). Our patient, however, had the nodular





FIGURE 2
Anterior (A) and lateral (B) ⁶⁷Ga images of the lower extremities obtained 72 hr after administration of 5.0 mCi of gallium. There is diffuse as well as multiple small focal areas of increased uptake scattered throughout both calf regions.



FIGURE 3

Anterior chest ⁶⁷Ga images show mild accumulation at the costo-chondral junctions bilaterally. There is no evidence of ⁶⁷Ga accumulation to suggest sarcoidosis in these regions.

form of muscular sarcoidosis, which was isolated to the calf muscles and produced severe symptoms. Gallium-67 imaging is a highly sensitive examination for detection of disease activity in patients with known sarcoidosis. Although this is well documented for patients with chest involvement, the true sensitivity of gallium imaging in muscular sarcoidosis is not known. Serial examinations, however, in patients with known muscular sarcoidosis have been show to be helpful (8,9).

There are many inflammatory disorders as well as tumors that can involve the extremities and cause avid 67 Ga uptake (7,10). It is often difficult to separate skin from muscle uptake in this type of study because of their close proximity and the relatively poor resolution of current camera systems. However, physical examination may help differentiate the two.

Many disorders that cause FUO will also cause abnormal ⁶⁷Ga accumulation and, therefore, correlation with clinical findings and other imaging modalities is necessary before making a final diagnosis. Nevertheless, ⁶⁷Ga imaging can direct one to an appropriate biopsy site as it did with our patient. With this is mind, one should always include an evaluation of the extremities during ⁶⁷Ga imaging in patients with FUO. Also, when abnormal ⁶⁷Ga accumulation is seen in the extremities, sarcoidosis should be included in the differential diagnosis.

REFERENCES

- Rohatgi PK, Singh R, Vieras F, et al. Extrapulmonary localization of gallium in sarcoidosis. Clin Nucl Med 1987;12:9– 16.
- Wallace SL, Lattes R, Malia JR, et al. Muscle involvement in Boeck's sarcoid. Ann Intern Med 1958;48:497-511.
- 3. Kaupp M, Chatton M. Current medical diagnosis and treatment. Los Alto, CA: Lange Publications, 1983:119-120.
- Silverstein A, Sietzbach LE. Muscle involvement in sarcoidosis. Asymptomatic, myositis, and myopathy. Arch Neurol 1969;21:235-241.
- Larson EB, Featherstone HJ, Petersdorf RG. Fever of undetermined origin. Diagnosis and follow-up of 105 cases, 1970– 1980. Medicine 1982;61:269–292.
- Nolan JP, Klastin G. The fever of sarcoidosis. Ann Intern Med 1964;61:455-461.

- Telenti A, Hermans PE. Idiopathic granulomatosis manifesting as fever of unknown origin. Mayo Clin Proc 1989;64:44–50
- 8. Edan G, Bourquet P, Delaval PH. Gallium-67 imaging in muscular sarcoidosis. *J Nucl Med* 1984;25:776-778.
- 9. Brown RG, Ash JM, Verellen D, et al. Gallium-67-citrate
- localization in carriers of Duchenne muscular dystrophy. *Int J Nucl Med Biol* 1981;8:379–388.
- Bodem CR, Hamory BH, Taylor HM, et al. Granulomatous bone marrow disease. A review of the literature and clinicopathologic analysis of 58 cases. *Medicine* 1983;62:372-383.

FEBRUARY 1961

Superimposed Optical and Gamma-Ray Scanner Images

Hal O. Anger and George M. Tisljar-Lentulis

Whole-body gamma-ray scanning has been used for some time to locate functioning thyroid tissue in patients suspected of metastatic thyroid disease. The patient is given a tracer dose of ¹³¹I and at 24–96 hr later is scanned to detect any lesions that may take up the isotope. When the gamma-ray image shows an area that concentrates ¹³¹I, the site of the uptake should be located as accurately as possible. One method is to superimpose the gamma-ray

Selected manuscripts from the issues of The Journal of Nuclear Medicine published 15 and 30 years ago.

Edited by F.F. Mand

image of an X-ray radiograph, as reported by West. The area of iodine concentration is thereby located with respect to the X-ray anatomy of the patient. However, this procedure increases the radiation dose received. Therefore, we have built an apparatus that automatically superimposes an optical photograph of the patient on the gamma-ray image.

The gamma-ray scanner used for this purpose employes ten scintillation counters mounted in a lead shield that moves over the patient. Each counter is connected to a glow lamp, which flashes with every count detected. As the counters move slowly over the patient, a moving image of the glow lamp is projected onto photographic film. The pattern of radioactivity is reproduced as a pattern of dots on the film. We have added a telephoto lens and mirror system to this, which allows photographing the patient on the same film. Magnification and location of the photographic image are such that it coincides exactly with the size and location of the gamma-ray image.

FEBRUARY 1976

Inadvertent lodine-131 Therapy for Hyperthyroidism in the First Trimester of Pregnancy

Sheldon S. Stoffer and Joel I. Hamburger

Although it is well known that [131] sodium iodide therapy after the 12th week of pregnancy may result in an hyperthyroid child, clinical data regarding such administration are lacking. This information would be useful, since inadvertent administration is most likely to occur early in pregnancy. As thyroid consultants, we are contacted 3–4 times each year by anxious physicians who have administered ¹³¹I for hyperthyroidism only to discover subsequently that the patient was a few weeks pregnant. The advisability of therapeutic abortion is the primary concern. The literature is surprisingly silent on this point.

Letters of inquiry (963) were sent to members of the American Thyroid Association and the Endocrine Society, who were selected based on their likelihood of treating thyroid patients. The physicians were asked:

- 1. How many of their thyroid patients had received therapeutic doses of ¹³¹I during the first trimester of pregnancy?
- 2. How many of these patients were advised to seek a therapeutic abortion?
- 3. How many of these patients carried to term under observation?
- 4. Of the deliveries, how many babies were observed with fetal abnormalities upon birth?

For the babies with abnormalities, the physicians were further asked to provide:

- 1. The estimated week of pregnancy of the ¹³¹I administration.
- 2. Urine pregnancy test results (if performed).
- 3. The date and dosage of 131I therapy.
- 4. Thyroid function tests results (if performed) in hyperthyroid infants, the age at which hyperthyroidism was diagnosed, indications of mental deficiencies (if any), and the child's current age.

Of the 963 physicians surveyed, 517 (54%) responded. A total of 237 patients inadvertently treated with ¹³¹I while pregnant were reported by 116/517 physicians.

When this survey was planned, we assumed that by this time everyone admin-

istering 131I therapy would routinely perform a pregnancy test for patients of childbearing age. Therefore, we did not request this information. However, 22 physicians offered comments indicating that our expectations were incorrect. For example, one physician said that he administered 131I therapy upon the request of the attending physician and was not a participant in the patient's clinical evaluation. Another physician indicated he was not concerned with pregnancy testing because it was his understanding that the fetal thyroid does not concentrate 131I in the first trimester, and that after the first trimester the diagnosis of pregnancy should be obvious.

The survey data suggest that the majority of physicians do not recommend therapeutic abortion for pregnant patients who inadvertently receive ¹³¹I therapy in the first trimester. This conservative approach seems justified by the finding that the rate of fetal and neonatal abnormalities was no greater than that reported for uncomplicated pregnancies. Of perhaps greater concern was the discovery that urine pregnancy tests are still not performed routinely, even in major medical centers.